Info

Scion Pharmaceuticals, Inc. discovers and develops small molecule drugs that selectively regulate ion channels, a well-established class of pharmaceutical targets with potential application for a wide range of major diseases. Scion applies an innovative ion channel drug discovery strategy that integrates functional biology and medicinal chemistry, and is enabled by its proprietary high-throughput electrophysiology assay (HTEPÔ). This approach allows the Company to evaluate ion channel subtype target function and effects of molecules on ion channels at the earliest stages of the drug discovery process. Scion is initially utilizing this approach to discover drugs for the treatment of cardiovascular and CNS disorders, with focus on atrial fibrillation and pain, respectively. Currently, the Company holds over 70 issued U.S. patents as well as foreign counterparts in many other countries.